Orum Therapeutics, Inc.
Financials
Valuation Metrics
Orum Therapeutics, Inc.'s Market Cap is ₩3343B. At end of 2025 it was ₩2.6T. Ranked #580 of 2,405 in KR market (top 24%), #233 of 1,627 on KOSDAQ (top 14%), #60 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 26%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 334.34B KRW | KR#580/2,405 Sec#60/231 |
| Revenue | 40.6M KRW | KR#2,379/2,405 Sec#225/231 |
| Net Income | 18.51B KRW | KR#731/2,405 Sec#48/231 |
| Total Assets | 169.32B KRW | KR#1,423/2,405 Sec#108/231 |
| Net Assets | 130.89B KRW | KR#1,224/2,405 Sec#92/231 |
| Employees | 21 | KR#2,232/2,405 Sec#212/231 |
| Value | ||
| P/E | 18.06x | KR#1,166/2,405 Sec#70/231 |
| P/B | 2.55x | KR#2,080/2,405 Sec#161/231 |
| P/S | 14188.55x | KR#2,397/2,405 Sec#228/231 |
| Profitability | ||
| ROE | 14.14% | KR#363/2,405 Sec#25/231 |
| ROA | 10.93% | KR#230/2,405 Sec#18/231 |
| Op. Margin | -161817.85% | KR#2,375/2,405 Sec#224/231 |
| Revenue Growth | -99.89% | KR#2,314/2,405 Sec#212/231 |
| Financial Health | ||
| Debt Ratio | 29.37% | KR#570/2,405 Sec#65/231 |
| Total Debt | 12.40B KRW | KR#1,547/2,405 Sec#137/231 |
| Cash | 4.07B KRW | KR#2,078/2,405 Sec#194/231 |
| Performance | ||
| 1Y Return | -66.59% | KR#2,268/2,405 Sec#218/231 |
| 1M Return | -27.33% | KR#2,159/2,405 Sec#214/231 |
| From 52W High | -89.52% | KR#2,384/2,405 Sec#228/231 |
| 1Y MDD | -89.34% | KR#2,384/2,405 Sec#228/231 |
| Trading | ||
| Volume | 78,258 shares | KR#738/2,405 Sec#77/231 |
| Trading Value | 1.20B KRW | KR#540/2,405 Sec#54/231 |
| Foreign Own. | 7.04% | KR#633/2,405 Sec#55/231 |
| Per Share | ||
| EPS | 851 KRW | KR#788/2,405 Sec#56/231 |
| BPS | 6,017 KRW | KR#1,368/2,405 Sec#96/231 |
Company Info
Orum Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic solutions for both cancer and immune system conditions. The firm specializes in creating degrader-antibody conjugates, an innovative class of drugs that merges traditional antibody-drug conjugate (ADC) technology with targeted protein degradation. Their flagship product candidate, ORM-1153, functions as a GSPT1 protein degrader, specifically engineered to address hematologic malignancies. Orum Therapeutics was established in 2016 and operates out of Daejeon, South Korea.